NWK Group’s Ligand Pharmaceuticals LGND Stock Holding History

NWK Group’s Portfolio LGND Stock Details LGND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-401	Closed	-$38K	–	128
2021 Q1	$38K	Buy	+401	New	+$37.9K	0.02%	118

Other funds holding LGND

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

SDJVC

St. Denis J. Villere & Co New Orleans, Louisiana $907M AUM 10.61% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Chicago Capital Chicago, Illinois $3.71B AUM 19.51% 1-Year Est. Return

CCA

Conestoga Capital Advisors Wayne, Pennsylvania $4.6B AUM 16.08% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

NWK Group's LGND Position: Q2 2021 in Review

NWK Group sold out of Ligand Pharmaceuticals (LGND) in Q2 2021, closing a stake of 401 shares — an estimated $38K sold.

NWK Group first reported a position in LGND in Q1 2021 and held it in 1 quarter. The position peaked at $38K in Q1 2021. 212 funds tracked by Wall St. Rank hold LGND as of Q2 2021.

NWK Group reported no remaining Ligand Pharmaceuticals position as of Q2 2021 after selling out during the quarter.
NWK Group sold 401 Ligand Pharmaceuticals shares in Q2 2021, an estimated $38K.
NWK Group first reported a position in Ligand Pharmaceuticals in Q1 2021 and held it in 1 quarter.
NWK Group's Ligand Pharmaceuticals position peaked at $38K in Q1 2021.
212 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2021.

Based on NWK Group's 13F filing for Q2 2021, filed 16 Aug 2021.